UBE2T showed an AUC of 0.977 to predict 3-year prognosis. UBE2T mono-ubiquiting FANCD2 is a critical process in ICL repair. Comet assay showed UBE2T knockdown-induced DNA damage, which is enhanced after MMC treatment. FANCD2 ubiquitin decreased after UBE2T knockdown. p-Chk1 and p-ATM increased when exposed to MMC. UBE2T expression level is related to immune receptors such as TNFRSF14, etc.

Conclusion/Implications A DDR genes nomogram with UBE2T as a key variable was identified. This study may help risk stratification and promote DDR agent and ICB use in endometrial cancer.

Natural Compound Baicalein Synergizes with AMP-Activated Protein Kinase Activator SR04 in Endometrial Cancer by Inhibition of PI3K/mTOR and STAT3 Without Activating AKT or MAPK

Ernest Han*, Jin Yan, Quanhua Xing, Wei Wen, Alison Dumitriu, James Figarola, John Yim. City of Hope, Department of Surgery, Duarte, USA

Introduction Loss of PTEN expression is common in endometrial cancer. The PI3K/mTOR pathway has been a target, but counter-regulatory pathways via Akt and ERK may hinder efficacy. We previously showed that the natural flavonoid baicalein inhibits cell growth via mTOR pathway. We investigated the effects of a novel AMPK activator SR04 in combination with baicalein in endometrial cancer.

Methods Endometrial cancer cell lines, RL95-2 and KLE were treated with varying concentrations of baicalein and SR04. Cell viability assessment at 72 hours was determined by MTT assay. Drug combination studies and synergy quantification was performed using Chou-Talalay method. Western blot analysis was utilized to evaluate PI3K/mTOR end targets.

Results Baicalein or SR04 alone inhibited proliferation of endometrial cancer cell lines in a dose dependent manner. In combination, baicalein and SR04 acted synergistically to inhibit cell proliferation, especially at low concentrations (figure 1). The synergistic effect was mediated by inhibition of STAT3 and PS6 as demonstrated on Western blot (figure 2). Interestingly compensatory activation of AKT and MAPK pathways,
which can oppose the anti-proliferative effects of PI3K/mTOR inhibition, was not observed with the combination of baicalin and SR04 on Western blots.

**Conclusion/Implications** The combination of baicalin and AMPK activator SR04 inhibits endometrial cancer cell proliferation in a synergistic manner. The combination does not appear to activate AKT and MAPK pathways which can hinder efficacy. The combination of baicalin and SR04 may offer a novel treatment paradigm for endometrial cancer.

**Methods** We present a retrospective case series of five patients who are undergoing fertility sparing treatment for early endometrial cancer, who also underwent bariatric surgery for treatment of obesity and related comorbidities. We aim to show early regression of endometrial cancer for all the patients and also report on the other health benefits of bariatric surgery.

**Results** All five patients in this series achieved regression of endometrial cancer within six months of undergoing bariatric surgery. They also achieved significant weight loss and three patients with obesity-related comorbidities had remission of these conditions. One patient conceived via in-vitro fertilization and delivered a healthy baby.

**Conclusion/Implications** Patients on fertility sparing treatment for endometrial cancer who underwent bariatric surgery achieved early cancer regression within six months, significant weight loss and resolution of obesity related comorbidities. Bariatric surgery could be a promising component of fertility sparing management for obese patients. Long term, prospective studies are required to confirm the benefits reported in this series.